These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 32165164)

  • 21. Evaluation of Time to Benefit of Statins for the Primary Prevention of Cardiovascular Events in Adults Aged 50 to 75 Years: A Meta-analysis.
    Yourman LC; Cenzer IS; Boscardin WJ; Nguyen BT; Smith AK; Schonberg MA; Schoenborn NL; Widera EW; Orkaby A; Rodriguez A; Lee SJ
    JAMA Intern Med; 2021 Feb; 181(2):179-185. PubMed ID: 33196766
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups.
    Gelbenegger G; Postula M; Pecen L; Halvorsen S; Lesiak M; Schoergenhofer C; Jilma B; Hengstenberg C; Siller-Matula JM
    BMC Med; 2019 Nov; 17(1):198. PubMed ID: 31679516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
    Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano A; Miccoli R; Bianchi C; Daniele G; Del Prato S
    Diabetes Res Clin Pract; 2020 Apr; 162():108112. PubMed ID: 32198123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the heterogeneity of the effects of SGLT-2 inhibitors in cardiovascular outcome trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Nutr Metab Cardiovasc Dis; 2020 Jan; 30(1):71-76. PubMed ID: 31757568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
    Zou CY; Liu XK; Sang YQ; Wang B; Liang J
    Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Class effect for SGLT-2 inhibitors: a tale of 9 drugs.
    Giugliano D; Esposito K
    Cardiovasc Diabetol; 2019 Jul; 18(1):94. PubMed ID: 31337395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin-associated incident diabetes: a literature review.
    Park ZH; Juska A; Dyakov D; Patel RV
    Consult Pharm; 2014; 29(5):317-34. PubMed ID: 24849689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
    Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
    J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Dana T; Blazina I; Daeges M; Jeanne TL
    JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.